|
<p align=justify>Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------------<p>Q2 2001: PULSION Medical Systems AG on course for strong growth Sales revenues surge strongly by 66% / Gross earnings margin further improved / Sales and marketing expenditures weigh heavily on result Munich, August 22, 2001 - PULSION Medical Systems AG, a life science company listed on the Frankfurt stock exchange`s Neuer Markt segment and specialized in medical diagnosis and therapy systems, today published results for the second quarter ending June 30, 2001. In comparison with business in H1 of 2000, PULSION has strongly increased sales revenues. They were up 66% to Euro 4.363 million from Euro 2.635 million. The gross earnings margin also increased most encouragingly. H1, 2001 gross margin increased to Euro 2.604 million from Euro 1.457 million. In relation to sales, productivity showed a further marked improvement to 59.7% from 55.3%. Operating results before depreciation (EBITDA) was Euro -2.634 million compared with Euro -1.789 million in H1 of 2000. The H1, 2001 Net income was Euro -3.509 million compared with Euro -2.368 million in H1, 2000. Expenditure on expanding international marketing and sales activities as well as the strengthening of research and development weighed heavily on results. A clear sign of the continued positive business development is the increase in the installed base of monitors with PiCCO technology, the company`s present core product. The installed PiCCOs grew 80% to 1,641 from 914, and sales of the present main source of sales revenue, the PiCCO disposable kit, increased strongly by 126%. PULSION aims to break even in 2002. Further highlights are: -CE mark for LiMON liver function monitoring system, EU sales are due to start in the third quarter with an EU and U.S. market potential of Euro 277 million per annum. -CE mark for IC-VIEW, the first imaging process suitable for measuring the blood perfusion of skin, muscles and organs, with an EU and U.S. market potential of Euro 186 million per annum. Full details of Q2 2001 results are to be found in the company`s second quarter report, which can be downloaded from http://www.pulsion.de<p><p> end of ad hoc announcement (c) DGAP 22.08.2001 -------------------------------------------------------------------------------- WKN: 548790; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart<p> 220734 Aug 01<p><br><br>Autor: DGAP import (),07:37 22.08.2001</p> |
|
| aus der Diskussion: | DGAP-Ad hoc: Pulsion Medical Syst. AG <DE0005487904> english = |
| Autor (Datum des Eintrages): | ad_hoc (22.08.01 07:37:08) |
| Beitrag: | 1 von 1 (ID:4254226) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |